Premier Alternatives

GEn1E Lifesciences

Palo Alto, CA · Founded 2018 · Privately Held (backing)

Developer of artificial intelligence-powered precision therapies designed to address immunology, inflammatory, rare, and oncologic diseases. GEn1E Lifesciences is based in Palo Alto, CA and was founded in 2018. It was valued at $136 million at its early-stage round in Dec 2025, the last priced event on record. It has raised $25.6 million across 2 recorded rounds; the latest was a $5.5 million early-stage round in Oct 2025.

PMV mark · valuation
$135.5M
Oct 2026
Priced at
its early-stage round
Dec 2025
Total raised
$25.6M
Last round
Early Stage VC
Oct 2025

GEn1E Lifesciences key facts

as of Oct 2026
  • Developer of artificial intelligence-powered precision therapies designed to address immunology, inflammatory, rare, and oncologic diseases.
  • GEn1E Lifesciences is valued at approximately $135.5M as of Oct 2026, set at its early-stage round, Dec 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $25.6M across 2 recorded rounds; the latest was Early Stage VC ($5.5M) in Oct 2025.
  • Notable investors include Y Combinator, Khosla Ventures, Gaingels, StartX (US), BoxOne Ventures — 38 tracked in total.
  • GEn1E Lifesciences has filed 1 Form D with the SEC, most recently Dec 2022 ($17.0M sold to 89 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$135.5M

Valued at $135.5M at its early-stage round, Dec 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of GEn1E Lifesciences with a free account
  • ·The complete investor list: 38 names
  • ·Watch GEn1E Lifesciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

GEn1E Lifesciences funding rounds

2 rounds
Oct 2025Early Stage VC$5.5MSEC filing▮
Dec 2022Early Stage VC$17.0MSEC filing▮
Full funding history →

GEn1E Lifesciences valuation

GEn1E Lifesciences was valued at $136 million at its early-stage round in Dec 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has GEn1E Lifesciences raised?

GEn1E Lifesciences has raised $25.6 million across 2 recorded rounds since 2022. The largest was a $5.5 million early-stage round in Oct 2025.

GEn1E Lifesciences has filed 1 Form D with the SEC, most recently in Dec 2022 ($17 million sold to 89 investors).

GEn1E Lifesciences investors

38 investors are on record for GEn1E Lifesciences, including Y Combinator, Khosla Ventures, Gaingels and StartX (US). The early-stage round in Oct 2025 drew 44 investors.

About GEn1E Lifesciences

Developer of artificial intelligence-powered precision therapies designed to address immunology, inflammatory, rare, and oncologic diseases. The company offers a proprietary drug development model that integrates mechanistic endotyping, kinase modulation, and data-driven clinical insights, enabling researchers and clinicians to accelerate discovery-to-clinic timelines, optimize treatment efficacy, and advance novel therapies for complex diseases.

Sector
Healthcare
HQ
Palo Alto, CA, United States
Founded
2018
Employees
6
Website
gen1e.com/
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.